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PROTOCOL
• Transfusion
• Endoscopic Evaluation or Intervention
• Perforation or Surgical Intervention
• ICU Upgrade
• Overt GI Bleeding
Patient #1
– Underuse of Prophylaxis
– Risk factors: male, NSAID 
and steroid, AKI, sepsis
– Event: Transfusion, Scope
Patient #2
– Underuse of Prophylaxis
– Risk factors: age, male, 
anticoagulation
– Event: Overt GI bleeding
Patient #3
– Underuse of Prophylaxis




– Correct use of Prophylaxis
– Risk factors: age, male, AKI, 
liver disease
– Event: Transfusion, ICU 
Upgrade, Death
Patient #5
– Correct use of Prophylaxis




– Correct use of Prophylaxis
– Risk factors: AKI
– Event: Transfusion
REFERENCES
1. Cook, D., Guyatt, G. 2018. “Review Article: prophylaxis against upper gastrointestinal 
bleeding in hospitalized patients.” NEJM 378 (26):  2506-2516. 
2. American Society of Health-System Pharmacists. “ASHP therapeutic guidelines on stress 
ulcer prophylaxis.” Am J Health-Syst Pharm. 1999; 56:347-79. 
3. Weinhouse, G., Manaker, S., Finlay, G. 2019. “Stress ulcer prophylaxis in the intensive care 
unit.” UpToDate. 
4. Qadeer, M, Richter, J., Brotman, D. 2006. “Hospital-acquired gastrointestinal bleeding 
outside the critical care unit.” Journal of Hospital Medicine 1 (1): 14-20.
5. Terdiman, J., Ostroff, J. 1998. “Gastrointestinal bleeding in the hospitalized patient: a 
case-controlled study to assess risk factors, causes, and outcome.” Am J Med 104: 349-
354.
6. Fiaccadori, E., et al. 2001. “Incidence, risk factors, and prognosis of gastrointestinal 
hemorrhage complicating acute renal failure.” Kidney Int 59: 1510-1519.
7. Herzig, S., Rotheberg, M., Feinbloom, D. 2013. “Risk factors for nosocomial 
gastrointestinal bleeding and use of acid-suppressive medication in non-critically ill 
patients.” J Gen Intern Med 28:  683-690.
8. Bui, T. 2019. “Adult Acid Suppression Guidelines.” The Capsule 1: 1-2.
Clinical Outcomes of Utilization of Stress Ulcer Prophylaxis 
in Hospitalized, Non-ICU Patients
Paige Robinson, DO, PGY-2 and Kate Radvansky, DO
RESULTS:  RATES OF BLEEDING
Figure 1. Percent of patients with clinically important bleeding (CIB) based 
on the use of stress ulcer prophylaxis. Three of 190 patients in the underuse 
category had clinically important bleeding events.  Three of 46 patients with correct use 
of prophylaxis had events.  The result of an ANOVA was  p = 0.156, conferring no 
statistical significance.
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Analysis:  Rates of clinically important bleeding per group?
Included: all remaining patients
BACKGROUND DISCUSSION
Definition of Clinically Important Bleeding
Definition, Pathogenesis, Incidence of Stress Ulcers
Definition
Superficial ulceration, erosion of gastric mucosa
Most commonly in stomach, but can occur in duodenum or esophagus
Pathogenesis1-3
Acid hyper secretion (especially neurologic and thermal injuries) due to excess 
gastric stimulation of parietal cells
Also stimulated by stress-triggered vagal stimulation
Pro-inflammatory state causes release of mediators: arachidonic acid 
metabolites, cytokines, oxygen free radicals 
Impaired mucosal protection
Decreased perfusion
Increased concentration of refluxed bills salts and uremic toxins 
Synthesis decreased due to poor gut perfusion from shock, sepsis, trauma
Start proximally in the acid-secreting portion of stomach, then progresses:  over 
time, become deeper and move distally
Wedge-shaped mucosal hemorrhages with necrosis of superficial mucosal cells; if 
progresses to submucosa, can cause significant and life-threatening bleeding
Incidence4-7
Range: 0.005% to 7.85%





•Acute renal failure (AKI)
Independent Risk Factors for Stress Ulcer Formation1,8
There is no statistically significant difference in clinically important 
bleeding based on correct or incorrect use of stress ulcer prophylaxis in 
hospitalized, non-ICU patients.  This is consistent with previous 
literature.  Use of stress ulcer prophylaxis on floor patients remains 
individualized by the clinician, who must give consideration to the 
specific patient and risk factors present.  Further studies are needed to 
determine if a certain number or combination of risk factors is 
significant rather than individual risk factors.
Patients with Clinically Important Bleeding Events
CONCLUSION
•Anticoagulation +/- antiplatelet agent
•NSAID and corticosteroid
























Use of Stress Ulcer Prophylaxis
Patients with CIB
Patients without CIB
This study is a retrospective chart review that aims to measure the effect of stress 
ulcer prophylaxis in hospitalized non-ICU level patients to determine the clinical 
effect of the presence or absence of stress ulcer prophylaxis.
Goal
